NL-OMON37770已完成不适用
PHASE I, DOUBLE BLIND, PLACEBO-CONTROLLED, DOSE-ESCALATION STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF FMX-8 IN HEALTHY MALE VOLUNTEERS - FMX-8 SAD and MAD study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- healthy male subjects
- •- 18-55 yrs, inclusive
- •- BMI: 18.0-30.0 kg/m2, inclusive
- •- non-smoking
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study
研究者
相似试验
进行中（未招募）
不适用
Safety and immunogenicity study of GlaxoSmithKline (GSK) Biologicals’ pneumococcal vaccine 2830930A when given as 1 dose to healthy toddlers aged 12-23 months.EUCTR2011-002225-22-DEGlaxoSmithKline Biologicals
已完成
不适用
A phase I, single-dose, double-blind, randomised, dose escalation study to assess the safety, tolerability and pharmacokinetics of NNZ-2566 when administered as a 10-minute infusioTraumatic brain injuryInjury, Occupational Diseases, PoisoningISRCTN67656669euren Pharmaceuticals (New Zealand)35
已完成
不适用
Study of egg-derived influenza vaccine and cell culture-derived influenza vaccine in healthy adult volunteersDiseases of the blood and blood -forming organs and certain disorders involving the immune mechanismKCT0001240SK Chemicals100
已完成
1 期
A phase I/II study to evaluate the Salmonella Typhi Vi polysaccharide vaccine – vax-TyVi – in children and teenagers.Typhoid Fever/preventionSalmonella InfectionsEnterobacteriaceae InfectionsGram-Negative Bacterial InfectionsBacterial InfectionsGastrointestinal DiseasesWaterborne DiseasesEnvironmental Illnesstyphoid feverRPCEC00000055Finlay Institute
已完成
1 期
A study to investigate how ENTR-601-44 behaves in the body, the safety and how well tolerated different increasing amounts of the drug ENTR-601-44 are when given to healthy male volunteersHealthy volunteersISRCTN36174912Entrada Therapeutics, Inc.32